This Ul0 application is in support of the CALGB Cooperative Group Clinical Trials conducted through the Wake Forest University School of Medicine (WFUSM) and its affiliate Members. WFUSM has been continuously awarded a CALGB U10 Grant for 45 years (CA03927) as the key support of the infrastructure for data management, the required administrative interactions with our Affiliate Members, and for the support of scientific and administrative contributions to CALGB. In addition to support for the Main Member, this U10 Grant supports the oversight of activity at our two current Affiliate Members, East Carolina University, Greenville, North Carolina and Carolina Oncology Associates of Salisbury, Salisbury, North Carolina.
The specific aims of this grant application are: ? * To increase our scientific contributions to Disease and Modality Committee activities ? * To enhance the participation of our clinical research investigators through the development of pilot data at the Comprehensive Cancer Center of Wake Forest University that can be developed into CALGB protocols ? * To expand the Affiliate Network of the Comprehensive Cancer Center of Wake Forest University in order to provide improved care of the cancer patient through access to CALGB Cancer Clinical Trials ? * To provide a clinical trials mechanism by which minority populations can accrue to clinical trails; to improve their proportional participation in clinical trials research; and to develop specific strategies to address regional barriers to minority recruitment and retention in clinical research studies ? * To continue our participation as a funded Prevention Member Center ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA003927-47
Application #
6741456
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1979-04-01
Project End
2009-03-31
Budget Start
2004-08-18
Budget End
2005-03-31
Support Year
47
Fiscal Year
2004
Total Cost
$261,471
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Gajra, Ajeet; McCall, Linda; Muss, Hyman B et al. (2018) The preference to receive chemotherapy and cancer-related outcomes in older adults with breast cancer CALGB 49907 (Alliance). J Geriatr Oncol 9:221-227
Vasu, Sumithira; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood Adv 2:1645-1650
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia 32:1338-1348
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. Leukemia 32:2536-2545
Kimmick, Gretchen G; Major, Brittny; Clapp, Jonathan et al. (2017) Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503). Breast Cancer Res Treat 163:391-398
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Uy, Geoffrey L; Mandrekar, Sumithra J; Laumann, Kristina et al. (2017) A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv 1:331-340
Cushman, Stephanie M; Jiang, Chen; Hatch, Ace J et al. (2015) Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Clin Cancer Res 21:1078-86
Morrison, Vicki A; Jung, Sin-Ho; Johnson, Jeffrey et al. (2015) Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). Leuk Lymphoma 56:958-64
Voorhees, Peter M; Orlowski, Robert Z; Mulkey, Flora et al. (2015) Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Br J Haematol 171:373-7

Showing the most recent 10 out of 209 publications